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Abstract 
 Chitosan and heparin were used to synthesize nanoparticles using polyelectrolyte 
complexation. The optimal mixing ratio was determined to be 1:4 by studying the particle 
characteristics of zeta potential and dynamic light scattering of the ratios 1:2, 1:3, 1:4, 1:5 and 1:6 
(chitosan: heparin). The particles were loaded with the antibiotic polyhexamethylene biguanide 
(PHMB) and the release was measured over 335 hours using the dialysis membrane incubation 
method1 and detected via ultraviolet-visible (UV-Vis) spectroscopy. Around 80% of the 
encapsulated PHMB was released over the measured period.  The goal of this part of the study was 
to determine the drug release behavior of chitosan-heparin nanoparticles and their viability as 
release agents for future wound healing applications. This study concluded that the performance 
of the particles exhibits sustained release over prolonged periods to be further investigated as 
transport agents. Antibacterial studies are needed to evaluate the effectiveness of the particles in 
vitro against gram-positive and gram-negative bacterial species.   
Executive Summary: 
Introduction: 
 Bacterial infection can occur during the process of wound healing which presents a 
significant obstacle for treating and covering open wounds.2 Transdermal delivery of antibiotic 
agents to the wound site allows for the continued healing via combating infection3.  The application 
of nanotechnology in drug delivery has increasingly gained prevalence in the past decade.7 This 
study focuses first on the design of heparin-chitosan based nanoparticles with an optimum 
morphology and polydispersity and then on the delivery of polyhexamethylene biguanide (PHMB) 
by means of heparin-chitosan nanoparticles (hep-cs NPs). The formation of particles occurs via 
polyelectrolyte complexation of chitosan and heparin, where the positively charged PHMB is 
encapsulated within the negatively charged particle. 
Results: 
 The optimal ratio of chitosan to heparin was determined to be 1:4 (chitosan: heparin 
volume ratio) among all the ratios tested (1:2, 1:3, 1:4, 1:5 and 1:6 (chitosan: heparin)). Hep-cs 
NPs synthesized, using the previously stated volume ratio, exhibit structural stability and 
uniformity with an average charge of -32.0±1.0 mV and average size of 198.2±34.0 nm in their 
plain state. After loading the particle with PHMB, the average charge was measured to be 
+56.9±1.1 mV with the average size of 531.8±18.6 nm. The encapsulate PHMB within the hep-cs 
NPs was found to have a controlled and sustained release over the period of 14 days, allowing 
most of the drug (79.8%) to be released.  
Conclusions: 
 Positively charged chitosan was added to negatively charged heparin in a ratio of 1:4 
(chitosan: heparin) to produce a negatively charged nanoparticle that encapsulated the positively 
charged antibiotic PHMB. The polysaccharide-based, hep-cs NPs are stable, well dispersed 
particles capable of encapsulating and releasing the antibiotic PHMB. The successful release 
activity exhibited by the particles indicates possible viability for use in wound dressings to prevent 
bacterial infection and promote regenerative behavior of dermal tissue. Using hep-cs NPs to 
deliver PHMB in wound healing can be a more cost-effective method than the more expensive, 
silver-based technologies.  
Skills and Experience Gained: 
 I have gained skills in laboratory techniques, experimental design, data analysis, and 
technical report writing while working on this project. I have become familiar with zeta potential 
testing, dynamic light scattering measurements, ultraviolet-visible spectroscopy, drug release 
study techniques, particle synthesis, and literature review. Working directly with a graduate 
student on this project has helped me gain insight on my own career path and affirmed my choice 
of continuing my education and pursuing research. I have increased my confidence in lab work 
and independence as I was given the opportunities to grow in these areas throughout the project.  
Recommendations: 
 Further research is needed to assess whether this solution is safe and effective both in-vitro 
and in-vivo. Cytotoxicity assays should be conducted to assess the safety of the loaded NPs against 
human dermal fibroblasts. Bacterial studies are needed to determine the concentrations at which 
PHMB kills bacterial cells. These data will determine whether the concentrations of PHMB 
released by hep-cs NPs, as shown in this study, will prevent bacterial infection while maintaining 
human dermal cell activity.  
  
Acknowledgements: 
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resources to complete this research and project. Special thanks to Shahrzad Fathollahipour for her 
guidance, time, effort, and willingness to assist me in this project.   
Introduction:  
In the process of wound healing, bacterial infection presents a significant issue, delaying 
and in some cases preventing the wound from healing.2 Preventing bacterial infection requires 
antibiotic treatment. Polyhexamethylene biguanide (PHMB) is an antibiotic that has been shown 
to perform effectively with regenerative benefit.4 Dermal tissue toxicity and biocide resistance are 
both risks associated with high concentrations of antiseptics which impair the wound healing 
process.  
Nanostructure use, notably in colloidal nanoparticles, has increased noticeably in the field 
of drug delivery within the last decade. Nanoparticles easily interact with biological molecules due 
to their sub-microscopic size.5 Chitosan has become prevalent in particulate drug delivery systems 
due to its positive charge and ability to bind to biological materials. Chitosan has also proved to 
be a safe and efficient for use in the pharmaceutical industry.67 
We have shown the ability of heparin-chitosan nanoparticles (hep-cs NPs) loaded with 
PHMB to act as a reliable antiseptic delivery agent to release PHMB over a prolonged amount of 
time in a controlled manner. The positively charged chitosan molecules bind to the negatively 
charged heparin and forms a nanoparticle structure with tailorable surface charge. Due to a 1:4 
mixture of chitosan: heparin, the resulting particle charge was negative allowing the positively 
charged PHMB to be encapsulated by the particle. Wound dressings can be created with a greater 
cost effectiveness without sacrificing efficacy, using PHMB in place of costlier silver-based 
particles. In this study, the composition ratio of hep-cs NPs is tailored to achieve best surface 
charge, size and polydispersity, and the release of PHMB is measured and evaluated.   
 
Background: 
Using nanoparticles in drug release applications appears to be a viable area of research 
imperative to multiples fields of study including biomedical and pharmaceutical industries.6 For 
instance, nanoparticles synthesized by chitosan and hyaluronic acid have shown to be effective 
carriers and release agents of heparin for the treatment of asthma.8 Using this mechanism of 
polyelectrolyte complexation, we desire to investigate a nanoparticle (PCN) that can maintain a 
controlled release of antiseptic of wound healing applications. 
Formation of polysaccharide-based PCNs has been shown to be affected by the charge 
mixing ratios, charge densities, and the way the two polyelectrolytes are added together. Formation 
of negatively charged hep-cs PCN can be from charge mixing ratios below 0.50.9 Negatively 
charged, the PCN will be able to encapsulate the positively charged PHMB molecules. Drug 
delivery by nanoparticles with chitosan has been shown to be an effective transporter of micro- 
and nanoparticles due to its mucoadhesive properties and ability to entrap molecules.4  
Nanoparticles based on heparin have been shown to be biodegradable, anticoagulant, and effective 
for antitumor therapy10.  
Experimental Methods:  
Preparing the acetate buffer solution: 
0.1 M acetic acid was made by adding 2.86 ml of glacial acetic acid supplied by EMD 
Millipore (EMD Millipore, Cleveland, Ohio, United States of America) to 497.14 ml of nanowater. 
0.1 M sodium acetate solution was made by dissolving 6.8 g sodium acetate trihydrate 
(ARMRESCO, Solon, Ohio, United States of America) in 500 ml nanowater. pH 5 acetate buffer 
solution was made by mixing the acetic acid solution and the sodium acetate solution by a volume 
ratio of 59:141 acetic acid solution: sodium acetate solution. The pH was verified to be 5 using 
Oakton Ion 510 series pH probe (Cole-Palmer, Vernon Hills, Illinois, United States of America).  
 
PHMB Calibration Curve: 
Ultraviolet-visible spectroscopy (UV-Vis) calibration of PHMB (BOC Sciences, Shirley, 
New York, United States of America) was created using concentrations of 600, 300, 200, 150, 100, 
50, 10, and 5 µg/ml in filtered nanowater. 600 µg/ml solution was made by dissolving 0.012 g of 
PHMB in 20 ml of filtered nanowater. The other concentrations of the calibration trend were 
created using serial dilutions of 600 µg/ml.  
 
Synthesis of hep-cs NPs: 
0.9 mg/ml solution of chitosan was made by dissolving 0.09 g of chitosan (90KDa, 20% 
DDA, supplied by Mycodev) in 100 ml of pH 5 acetate buffer. 0.95 mg/ml heparin solution was 
made by dissolving 0.285 g heparin sodium salt from porcine intestinal mucosa (Sigma Aldrich, 
St. Louis, Missouri, united States of America) in 300 ml of acetate buffer. Solutions of 25 ml total 
volume were made with volume ratios of 1:2, 1:3, 1:4, 1:5, and 1:6 (chitosan: heparin) for 
determination of optimal mixing ratio. The solutions were washed by centrifugation with a speed 
of 5,000 × G for 20 minutes and the supernatant was replaced with equal volume of filtered 
nanowater. Particle solutions were frozen at -80ºC and freeze-dried for storage.  
 
Particle Loading: 
A solution of 1 mg/ml PHMB was made by dissolving 0.50 g of PHMB in 50 ml filtered 
nanowater. 14 ml of solution was added dropwise to each nanoparticle suspension after washing 
while maintaining 800 rpm stirring speed. The solutions remained under 800 rpm stirring for 24 
hours. The solutions were decanted into 50 ml centrifuge tubes and centrifuged for 20 minutes at 
5,000 × G. 30 ml of supernatant was stored in the freezer and replaced with filtered nanowater. 
The solutions were centrifuged again for 20 minutes at a speed of 5,000 × G. The supernatant was 
removed and stored in the freezer and freeze dried for storage. The particles were re-suspended in 
20 ml of filtered nanowater.  
 
PHMB Release: 
5 ml of PHMB loaded hep-cs NP solution was placed into 12 - 14 kDa MWCO-cut off 
dialysis membrane (Spectrum Labs, Rancho Dominguez, California, USA) and submerged into 
100 ml of phosphate-buffered-saline (PBS) in a light protected vessel. This was repeated for a total 
of 3 replicates. The samples were kept in a thermostatically controlled water bath set at a 
temperature of 37ºC. 300 µl samples of solution were removed and replaced with fresh PBS at 
time intervals between 0.5 hours and 335 hours as indicated in Figure 4.  
 
PHMB Concentration Measurement for Release and Calibration: 
Concentration measurements were made were made by measuring absorbance with 
ultraviolet-visible spectroscopy using Tecan Infinite® M200 and 16-well Tecan NanoQuant 
Plate™. A 2 µl drop of PHMB solution were placed on the NanoQuant plate and placed into the 
UV-vis spectrometer. The Absorbance was measured and concentration was calculated using 
Equation 1.  
Size and Zeta Potential Measurement Before and After PHMB Loading: 
Size and zeta potential measurements were made using dynamic light scattering and zeta 
potential readings by Zetasizer Nano Z analyzer and Malvern Zetasizer Nano Series Disposable 
Folded Capillary Cells (Malvern Analytical, Almelo, Netherlands).  
Data and Results:  
Chitosan-heparin nanoparticles were successfully synthesized by polyelectrolyte 
complexation. Size and PDI results indicate that the particles were stable and uniformly 
distributed. Particles were synthesized using volume ratios of 1:2, 1:3, 1:4, 1:5, and 1:6 
Figure 1. Shows the charge and size measurements of plain particles synthesized 
using the ratios of 1:2, 1:3, 1:4, 1:5, and 1:6 (chitosan: heparin). (Data all n=3, 
mean±S.D. ** indicates One-Way ANOVA, Tukey’s Post Hoc, P<0.0002) 
Hep-cs Nanoparticle Size and Zeta 
Potential versus Volume Ratio 
(chitosan/heparin). The ratio of 1/4 was selected as the optimal ratio due to particle size of 136.5 
nm and a charge of -42.4 mV.  
Table 1. Polydispersity index of each nanoparticle formulation 
Group 
Chitosan Conc. 
(mg/ml) 
Heparin 
Conc. 
(mg/ml) 
Chitosan to 
Heparin 
ratio 
PDI 
1 0.9 0.95 1/2 0.209±0.02 
2 0.9 0.95 1/3 0.193±0.017 
3 0.9 0.95 1/4 0.201±0.014 
4 0.9 0.95 1/5 0.200±0.027 
5 0.9 0.95 1/6 0.199±0.031 
 
Using 1/4 chitosan/heparin ratio, particles were synthesized and loaded with PHMB. Size 
and charge measurements were made before and after loading. The particle size before loading. 
The particle zeta potential measured was -32.0±1.0 mV. The zeta potential of the PHMB loaded 
nanoparticle was +56.9±1.1 mV. The particle size was found to be 198.2±34.0 nm before PHMB 
loading and 531.8±18.6 nm after loading.  
Figure 2. The zeta potential of chitosan-heparin nanoparticles before (plain) and 
after PHMB loading. (Data all n=3, mean±S.D.) 
Hep-CS Particle Zeta Potential Before 
and After PHMB Loading 
Figure 3. Size measurements of particles before (plain) and after PHMB loading. 
Error bars represent standard deviation. (Data all n=3, ** P<0.0022, mean±S.D.) 
Hep-CS Particle Size Before and After 
PHMB Loading 
 Calibration curve of PHMB using UV-Vis spectroscopy resulted in a linear curve with 
the following equation: 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 0.00352 × 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 − 0.0443  Equation 1 
The calibration curve in Figure 1 was used to calculate concentrations of PHMB in release 
samples and cumulative release percentage shown in Figure 4 using Equation 1. The calibration 
trend shown in the figure was created using a linear regression of absorption data with an R-
squared value of 0.997.  
The release of PHMB from hep-cs nanoparticles is shown in Figure 5. Controlled release 
was observed over the measured period. After a total of 335 hours, 79.89% of PHMB loaded into 
the hep-cs NPs was released. Cumulative release was determined using the initial amount of 
PHMB of 140 mg. Appendix 1 shows the cumulative release percentage calculated at each time 
point. Cumulative release percentage at time t (hours) was determined by the equation: 
(∑
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 ×𝑃𝐵𝑆 𝑣𝑜𝑙𝑢𝑚𝑒 × 𝑆𝑎𝑚𝑝𝑙𝑒 𝑉𝑜𝑙𝑢𝑚𝑒
𝑡𝑜𝑡𝑎𝑙 𝑚𝑔 𝑃𝐻𝑀𝐵 𝑙𝑜𝑎𝑑𝑒𝑑 𝑖𝑛𝑡𝑜 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑡
0 ) × 100 = 𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 %   Equation 2  
 Figure 4. The calibration curve for Absorption of PHMB. Error bars represent 
standard deviation (n=3; mean±S.D.). 
PHMB Ultraviolet-Visible Spectroscopy Calibration 
 Discussion/Analysis: 
Polyelectrolyte complexation of chitosan and heparin form stable nanoparticle structures 
and provide an effective release delivery system for PHMB.  Mixing using a ratio of 1:4 (Chitosan: 
Heparin) results in a stable particle sufficient in encapsulating PHMB, confirming methods used 
by Boddohi et al [3]. Using four times more heparin that chitosan creates a negatively charged 
particle due to the excess of negative charges from heparin, as seen by Figure 3. The loading of 
PHMB into the particle increases the zeta potential drastically due to the encapsulating of the 
positively charged molecule. Packing the particle with the large polymer also increases the particle 
size significantly, which is shown in Figure 4. The release study shown in Figure 5 suggests that 
using hep-CS NPs to deliver PHMB will effectively provide a less-expensive, yet effective method 
of preventing bacterial infection in wound healing applications over prolonged periods.  
Figure 5. The Cumulative release percentage of PHMB measured over time. Error bars 
represent standard deviation (Data all n=3, mean±S.D). 
Cumulative PHMB Release  
Errors present in this study are shown in the graphs and figures as standard deviation 
values. Additional errors present include human measurement errors due to pipetting, dry weight 
transfer loss, and instrument error. All measurements taken were made in triplicate with no 
prominent outliers.  
Conclusion: 
Heparin-chitosan nanoparticles formed by polyelectrolyte complexation exhibit stability in 
charge, size and drug release over prolonged periods. Further study is required before 
implementation of this technology. Cytotoxicity of PHMB released from nanoparticles should be 
studied to show that the amount of antibiotic released is able to kill bacteria without damaging the 
dermal tissue of the wound area. Additional research is recommended to evaluate the effectiveness 
of hep-CS NPs for delivery of additional molecules such as growth factors.   
Appendix 1: Cumulative PHMB Release from Hep-cs Nanoparticles 
Hours AVG Cumulative 
Release % of PHMB 
Standard 
Deviation 
0.35 0.72 0.20 
0.85 1.70 0.43 
1.35 2.92 0.88 
2.35 4.37 1.24 
3.43 6.07 1.65 
4.35 7.96 2.14 
5.60 9.93 2.63 
23.05 12.40 3.23 
25.10 14.90 3.83 
26.95 17.41 4.46 
28.35 19.97 5.08 
30.35 22.52 5.72 
46.93 25.12 6.34 
48.68 27.71 6.95 
50.77 30.30 7.58 
53.35 32.91 8.18 
72.02 35.31 8.74 
73.18 37.70 9.31 
77.18 40.10 9.81 
97.60 42.52 10.39 
99.68 44.93 10.96 
144.27 47.35 11.54 
148.85 49.85 12.14 
166.85 52.33 12.73 
169.60 54.84 13.34 
173.35 57.34 13.94 
190.85 59.89 14.51 
193.10 62.46 15.10 
194.85 65.04 15.67 
214.85 67.59 16.22 
220.85 70.12 16.71 
238.85 72.64 17.26 
240.85 75.10 17.81 
243.08 77.51 18.39 
335.10 79.89 19.00 
  
Appendix 2: Nomenclature 
Hep-cs: heparin - chitosan 
NPs: nanoparticles 
PCN: polyelectrolyte complex nanoparticle 
PHMB: polyhexamethylene biguanide 
UV-vis: Ultraviolet-visible spectroscopy 
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